Table 1.
Treatment | ||||
---|---|---|---|---|
Subunit | Control LDa | EtOH LDa | CeN Threshold Cycleb | Relative to Forebrain Expressionc |
NR1 | 2.39±0.21 | 2.22±0.20 | 24.4±0.5 | 0.80±0.05 |
NR2A | 1.99±0.32 | 2.39±0.31 | 25.8±0.3 | 0.48±0.04 |
NR2B | 1.91±0.13 | 1.86±0.12 | 23.7±0.3 | 0.74±0.06 |
NR2C | 1.74±0.04 | 1.73±0.05 | 28.3±0.2 | 0.59±0.04 |
NR2D | 2.58±0.43 | 2.38±0.25 | 30.6±0.3 | 1.42±0.15 |
NR3A | 1.77±0.20 | 1.97±0.23 | 28.0±0.3 | 0.53±0.08 |
NR3B | 2.32±0.18 | 2.53±0.26 | 29.1±0.2 | 0.85±0.03 |
– values are normalized to GAPDH levels determined for each sample (See Methods section) and are not representative of absolute expression levels.
– Threshold cycles (Ct) for central amygdala samples were collapsed across treatments. Assuming equivalent efficiencies for cDNA and PCR product formation, ‘1’ Ct unit would be equivalent to a 2-fold difference in expression.
– values = 2(−ΔCt) where ΔCt is the difference between the threshold cycles for equivalent masses of total forebrain RNA and our samples (collapsed across treatments). Values close to ‘1’ would indicate expression levels equivalent to total forebrain.